TL;DR
Researchers have developed a novel, high-throughput affinity mass spectrometry (MS) method to screen for small molecule ligands that interact with G protein-coupled receptors (GPCRs) directly within cell membranes. This label-free approach bypasses the need for costly and difficult protein purification, enabling the discovery of both orthosteric and allosteric modulators, including previously unreported compounds for the 5-HT2C and GLP-1 receptors.
What Problem Does This Paper Address?
GPCRs are a crucial class of drug targets, involved in a vast array of physiological processes and targeted by a significant portion of marketed drugs. However, identifying novel ligands for GPCRs, especially allosteric modulators, is challenging. Existing methods like functional assays can be indirect and struggle to identify allosteric binders, while radioligand binding assays are expensive and can be affected by fluorescent tags. Techniques like SPR and NMR require highly purified, stable receptors, which are often difficult to obtain for membrane proteins. This creates a need for more efficient, label-free, and unbiased screening methods that can work with receptors in their native membrane environment.
Methods
The core innovation is an affinity mass spectrometry (MS) screening approach that utilizes target-expressing cell membranes instead of purified proteins. The workflow involves:
- Incubation: Cell membranes expressing the target GPCR are incubated with a cocktail of small molecules.
- Separation: The cell membranes (and bound ligands) are separated from unbound compounds via filtration.
- Elution & Analysis: Ligands bound to the receptor are eluted from the membranes and then analyzed using liquid chromatography coupled to high-resolution mass spectrometry (LC-MS).
- Binding Index (BI): A "Binding Index" (BI) is calculated as the ratio of the MS signal of a compound in the target membrane incubation versus a control (using membranes expressing a non-target protein, like rhodopsin). A BI > 2 is used to identify potential binders.
This method is label-free for both the receptor and the compounds, and it works directly with cell membranes, eliminating the need for protein purification and stabilization.
Datasets
The study used a library of 4333 small molecules purchased from Topscience, which was divided into nine cocktails for screening.
Key Insights and Ideas
- Native Environment Screening: The ability to screen ligands directly within cell membranes is a significant advantage, preserving the receptor's native conformation and potentially revealing interactions missed with purified proteins.
- Unbiased Allosteric Modulator Discovery: The method's label-free and direct binding measurement nature makes it well-suited for identifying allosteric modulators, which often have different binding characteristics than orthosteric ligands.
- Efficiency and Cost-Effectiveness: Eliminating the protein purification step drastically reduces experimental cost and time, making large-scale screening more feasible.
- Validation of Novel Ligands: The discovery of previously unreported modulators for both 5-HT2C and GLP-1 receptors validates the approach's power.
- Differential Binding to Wild-Type vs. Mutated Receptors: The GLP-1R screening highlighted a crucial point: ligands identified using wild-type receptors showed abrogated binding to a thermostabilized, mutated receptor, underscoring the importance of screening in the native state.
Key Results
- 5-HT2C Receptor: The screening of 4333 compounds identified one novel antagonist for the human 5-HT2C receptor (compound 3943). This compound also showed antagonist activity against 5-HT2A and 5-HT2B receptors.
- GLP-1 Receptor: The screening identified four novel positive allosteric modulators (PAMs) for the human GLP-1 receptor. These compounds promoted intracellular cAMP accumulation in the presence of GLP-1 and showed high selectivity for GLP-1R over the closely related glucagon receptor (GCGR).
Limitations and Future Work
- Detectability of Compounds: A noted limitation is the detectability of certain compounds by the LC-MS platform, with only 66-86% of compounds in a cocktail being detected. This could be improved with more sensitive MS instruments or optimized LC conditions.
- Further Characterization: While novel ligands were identified, their precise targeting sites and activation mechanisms require further investigation.
- Adaptability: The authors suggest the approach is readily adaptable to other membrane receptors and can be integrated with complementary biophysical and functional assays for comprehensive drug discovery.
- Delineating Interactions: The method is expected to aid in mapping the broader network of membrane protein-small molecule interactions within cells.
Summary updated